ReviewCanadian journal of psychiatry. Revue canadienne de psychiatrie2017
The State of Opioid Agonist Therapy in Canada 20 Years after Federal Oversight.
Review in Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 4 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Oral and injectable opioid agonist treatments for people who use street opioids: a systematic literature review and network meta-analysis.BMC public health · 2025Pooled it
- Examining inequities in access to opioid agonist treatment (OAT) take-home doses (THD): A Canadian OAT guideline synthesis and systematic review.The International journal on drug policy · 2024Pooled it
- Assessing HIV and overdose risks for people who use drugs exposed to compulsory drug abstinence programs (CDAP): A systematic review and meta-analysis.The International journal on drug policy · 2021Pooled it
- Management of opioid use disorders: a national clinical practice guideline.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2018Guideline
- Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.Addiction (Abingdon, England) · 2022Trial
- "It's so much easier for them to just come to us": a qualitative study examining the implementation of mobile methadone treatment serving a residential SUD treatment program.Addiction science & clinical practice · 2026Article
- Participant perspectives on a safe supply program in Vancouver, Canada: impacts, satisfaction and improvement priorities.Harm reduction journal · 2026Article
- Article
- Opioid dispensing prior to opioid toxicity hospitalizations and emergency department visits in Canada, 2018-2022.PloS one · 2026Article
- Harnessing telemedicine to deliver patient-centered opioid agonist treatment within a community-based harm reduction service: a mixed methods evaluation.Harm reduction journal · 2025Article
- Examining opioid agonist treatment (OAT) site operations and early signals of change in the first year of British Columbia's drug decriminalization policy: Insights from a provincial survey.Canadian journal of public health = Revue canadienne de sante publique · 2025Article
- Primary care physician characteristics associated with becoming opioid agonist treatment prescribers in British Columbia: a retrospective case-control study.Harm reduction journal · 2025Article
- Disparities in Opioid Agonist Treatment Accessibility for Priority Populations in New South Wales, Australia.Drug and alcohol review · 2025Article
- Understanding the use of telemedicine across different opioid use disorder treatment models: A scoping review.Journal of telemedicine and telecare · 2025Article
- Barriers and facilitators to safer supply pilot program implementation in Canada: a qualitative assessment of service provider perspectives.Harm reduction journal · 2025Article
- Opioid analgesics for chronic noncancer pain in patients prescribed opioid agonist therapy or with opioid use disorder: A systematic review.Canadian journal of pain = Revue canadienne de la douleur · 2025Review
- Identifying opioid agonist treatment prescriber networks from health administrative data: A validation study.PloS one · 2025Article
- An Indigenous-led buprenorphine-naloxone treatment program to address opioid use in remote Northern Canada.Dialogues in health · 2024Article
- Reframing conceptualizations of primary care involvement in opioid use disorder treatment.BMC primary care · 2024Article
- Assessing support for substance use policies among the general public and policy influencers in two Canadian provinces.Substance abuse treatment, prevention, and policy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opioid agonist therapy was introduced in Canada in 1959 with the use of methadone for the treatment of opioid dependence. The regulation of methadone was the responsibility of Health Canada until 1995, when oversight was transferred to the provincial health systems. During the more than 20 years since the federal health authority transferred oversight of methadone to the provincial level, methadone programming has evolved differently in every province. The landscape of opioid dependence treatment is varied across the country, with generally increasing treatment capacity in all provinces and dramatic increases in some. Each province has an independent methadone program with differing policies, contingency management strategies, laboratory monitoring policies, and delivery methods. Treatment options have increased, with buprenorphine- and heroin-assisted treatment becoming available to limited degrees. Despite this, access remains a challenge in many parts of the country (particularly rural and remote areas) because the demand for treatment has increased even more rapidly than the capacity. Although treatment access remains a priority in many jurisdictions, there is also a need to attend to treatment quality as treatment access expands, including integration with addiction counselling, primary care, and mental health care. As well, coordinated monitoring and reporting of treatment need, quality, and delivery are required; implementing a national policy to promote planning would have tremendous value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.